Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis.
Kidney stones were passed by ten out of 186 patients with endstage renal disease who were treated with continuous ambulatory peritoneal dialysis (CAPD). Stones from seven patients were examined by x-ray diffraction. In five of them the stones were composed of calcium oxalate monohydrate. The urine calcium oxalate activity product was determined in 44 CAPD patients, eight of whom were stone formers, and compared to that of 120 normal volunteers. In CAPD patients, mean urine ionic-calcium concentration was lower than in normal subjects whereas mean urine ionic-oxalate concentration was significantly higher than in normal subjects. In normal urine samples, the calcium oxalate activity product showed a significant correlation with both the urine ionic-calcium and the ionic-oxalate concentrations. In contrast, in CAPD patients the calcium oxalate activity product correlated with the ionic-calcium concentration but not with ionic-oxalate. Although the urine ionic-calcium concentration is lower in CAPD patients than in normal subjects, it is the relative increase in its concentration which appears to be associated with the increased risk of kidney stone formation in these patients. This relative hypercalciuria seems to follow 1,25(OH)2 vitamin D3 administration.
D002117:Calcitriol / Q000494:pharmacology; D002118:Calcium / Q000097:blood / Q000652:urine; D002129:Calcium Oxalate / Q000378:metabolism* / Q000652:urine; D004100:Dihydroxycholecalciferols / Q000009:adverse effects; D006801:Humans; D007477:Ions; D007669:Kidney Calculi / Q000209:etiology*; D008854:Microscopy, Electron; D008855:Microscopy, Electron, Scanning; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D014961:X-Ray Diffraction
D004100:Dihydroxycholecalciferols; D007477:Ions; D002129:Calcium Oxalate; D002117:Calcitriol; D002118:Calcium